These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31752905)

  • 1. Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial.
    Hoffman KA; Baker R; Kunkel LE; Waddell EN; Lum PJ; McCarty D; Korthuis PT
    BMC Health Serv Res; 2019 Nov; 19(1):862. PubMed ID: 31752905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.
    Hoffman KA; Baker R; Fanucchi LC; Lum PJ; Kunkel LE; Ponce Terashima J; McCarty D; Jacobs P; Korthuis PT
    Addict Sci Clin Pract; 2021 Nov; 16(1):67. PubMed ID: 34758887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
    Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D;
    Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
    Korthuis PT; Cook RR; Lum PJ; Waddell EN; Tookes H; Vergara-Rodriguez P; Kunkel LE; Lucas GM; Rodriguez AE; Bielavitz S; Fanucchi LC; Hoffman KA; Bachrach K; Payne EH; Collins JA; Matthews A; Oden N; Jacobs P; Jelstrom E; Sorensen JL; McCarty D
    Addiction; 2022 Jul; 117(7):1961-1971. PubMed ID: 35129242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
    Gauthier P; Greco P; Meyers-Ohki S; Desai A; Rotrosen J
    J Subst Abuse Treat; 2021 Mar; 122():108183. PubMed ID: 33162260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
    Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
    J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release naltrexone for youth with opioid use disorder.
    Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
    J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
    Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
    Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
    Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
    Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.
    Marciuch A; Brenna IH; Weimand B; Solli KK; Tanum L; Røstad BK; Birkeland B
    Addict Sci Clin Pract; 2022 Jul; 17(1):36. PubMed ID: 35850782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
    Farabee D; Condon T; Hallgren KA; McCrady B
    J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
    Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
    Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
    Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
    J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.
    Biondi BE; Frank CA; Forray A; Springer SA
    Subst Abus; 2021; 42(4):905-911. PubMed ID: 33750285
    [No Abstract]   [Full Text] [Related]  

  • 16. Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.
    Cook RR; Torralva R; King C; Lum PJ; Tookes H; Foot C; Vergara-Rodriguez P; Rodriguez A; Fanucchi L; Lucas GM; Waddell EN; Korthuis PT
    Drug Alcohol Depend; 2021 Nov; 228():109077. PubMed ID: 34600253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study.
    Greiner MG; Shulman M; Opara O; Potter K; Voronca DC; Tafessu HM; Hefner K; Hamilton A; Scheele C; Ho R; Dresser L; Jelstrom E; Fishman M; Ghitza UE; Rotrosen J; Nunes EV; Bisaga A
    Contemp Clin Trials; 2023 May; 128():107148. PubMed ID: 36931426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 19. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
    Lier AJ; Seval N; Vander Wyk B; Di Paola A; Springer SA
    J Subst Abuse Treat; 2022 Nov; 142():108852. PubMed ID: 35988513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder.
    Fishman M; Wenzel K; Vo H; Wildberger J; Burgower R
    Addiction; 2021 Mar; 116(3):548-557. PubMed ID: 32621368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.